Pascal Soriot Purchases 20,000 Shares of AstraZeneca PLC (LON:AZN) Stock

AstraZeneca PLC (LON:AZN) insider Pascal Soriot bought 20,000 shares of the firm’s stock in a transaction on Thursday, November 14th. The stock was acquired at an average cost of £102.03 ($128.58) per share, with a total value of £2,040,600 ($2,571,644.61).

AstraZeneca Stock Performance

Shares of AZN opened at GBX 9,978 ($125.75) on Friday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. AstraZeneca PLC has a 12 month low of GBX 9,461 ($119.23) and a 12 month high of £133.88 ($168.72). The firm has a fifty day simple moving average of £116.38 and a 200 day simple moving average of £121.23. The stock has a market capitalization of £154.66 billion, a price-to-earnings ratio of 3,167.62, a PEG ratio of 0.86 and a beta of 0.17.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on AZN shares. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a £110 ($138.63) price target on shares of AstraZeneca in a report on Tuesday, September 3rd. JPMorgan Chase & Co. restated an “overweight” rating and set a £140 ($176.43) price objective on shares of AstraZeneca in a report on Thursday, November 7th. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a £150 ($189.04) target price on shares of AstraZeneca in a research note on Monday, September 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Moderate Buy” and an average price target of £104.12 ($131.22).

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.